China Biologic Products (CBPO) Upgraded to “Hold” at BidaskClub

China Biologic Products (NASDAQ:CBPO) was upgraded by stock analysts at BidaskClub from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

Other equities analysts have also issued reports about the stock. Jefferies Group reaffirmed a “buy” rating and set a $97.00 target price on shares of China Biologic Products in a research report on Thursday, March 15th. Zacks Investment Research raised shares of China Biologic Products from a “sell” rating to a “hold” rating in a research report on Monday, February 5th. TheStreet lowered shares of China Biologic Products from a “b-” rating to a “c+” rating in a research report on Thursday, March 1st. Finally, Deutsche Bank set a $105.00 target price on shares of China Biologic Products and gave the stock a “buy” rating in a research report on Friday, March 2nd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $101.00.

How to Become a New Pot Stock Millionaire

Shares of NASDAQ CBPO opened at $84.78 on Friday. The stock has a market capitalization of $2,809.02, a price-to-earnings ratio of 17.13, a PEG ratio of 1.29 and a beta of 1.46. China Biologic Products has a 1 year low of $71.85 and a 1 year high of $120.46.

China Biologic Products (NASDAQ:CBPO) last issued its earnings results on Wednesday, February 28th. The biopharmaceutical company reported $0.90 EPS for the quarter, topping the Zacks’ consensus estimate of $0.89 by $0.01. The business had revenue of $90.10 million for the quarter, compared to analyst estimates of $85.15 million. China Biologic Products had a net margin of 18.34% and a return on equity of 21.30%. The company’s quarterly revenue was up 16.1% compared to the same quarter last year. During the same period last year, the company posted $0.95 earnings per share. equities analysts forecast that China Biologic Products will post 5.22 EPS for the current year.

Several large investors have recently modified their holdings of the company. Millennium Management LLC increased its position in shares of China Biologic Products by 42.7% during the fourth quarter. Millennium Management LLC now owns 33,176 shares of the biopharmaceutical company’s stock worth $2,613,000 after acquiring an additional 9,932 shares during the period. Two Sigma Investments LP grew its holdings in China Biologic Products by 124.9% in the fourth quarter. Two Sigma Investments LP now owns 44,704 shares of the biopharmaceutical company’s stock worth $3,521,000 after purchasing an additional 24,826 shares during the last quarter. York Capital Management Global Advisors LLC grew its holdings in China Biologic Products by 430.9% in the fourth quarter. York Capital Management Global Advisors LLC now owns 160,847 shares of the biopharmaceutical company’s stock worth $12,670,000 after purchasing an additional 130,549 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in China Biologic Products by 854.7% in the fourth quarter. Goldman Sachs Group Inc. now owns 597,399 shares of the biopharmaceutical company’s stock worth $47,057,000 after purchasing an additional 534,824 shares during the last quarter. Finally, Rudman Errol M grew its holdings in China Biologic Products by 6.7% in the fourth quarter. Rudman Errol M now owns 28,701 shares of the biopharmaceutical company’s stock worth $2,261,000 after purchasing an additional 1,800 shares during the last quarter. 56.27% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “China Biologic Products (CBPO) Upgraded to “Hold” at BidaskClub” was posted by Ticker Report and is owned by of Ticker Report. If you are viewing this story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The correct version of this story can be read at https://www.tickerreport.com/banking-finance/3342327/china-biologic-products-cbpo-upgraded-to-hold-at-bidaskclub.html.

China Biologic Products Company Profile

China Biologic Products Holdings, Inc engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia.

Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Logitech  Expected to Post Earnings of $0.26 Per Share
Logitech Expected to Post Earnings of $0.26 Per Share
Perrigo  Given a $105.00 Price Target by Canaccord Genuity Analysts
Perrigo Given a $105.00 Price Target by Canaccord Genuity Analysts
Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Proteostasis Therapeutics  Stock Price
Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Proteostasis Therapeutics Stock Price
FTD Companies  Getting Somewhat Positive Press Coverage, Report Shows
FTD Companies Getting Somewhat Positive Press Coverage, Report Shows
Koovs  Stock Price Up 28.2%
Koovs Stock Price Up 28.2%
Rigel Pharmaceuticals   Shares Down 6.5%
Rigel Pharmaceuticals Shares Down 6.5%


© 2006-2018 Ticker Report. Google+.